Prevention of urinary infections as a complication in endoscopic surgery
Abstract
With regard to the changing resistance of microorganisms it is important to develop and test steadily new chemotherapeutic agents. The authors used the preparation CIPROBAY of Bayer Co. (ciprofloxacin) prophylactically in 60 patients of a group before instrumental endoscopic examination of before endoscopic operation. Evaluation of the results of Ciprobay administration revealed a high antibacterial and very good tolerance and simple administration of the preparation.
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.